Aurantiamide
Catalog No: CFN98984
Aurantiamide acetate has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux, it also inhibits cysteine proteinases, in particular, cathepsin L (3.4.22.15) and B (3.4.22.1) with IC50 of 12 microM and 49 microM, respectively . Aurantiamide acetate has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways.
Aurantio-obtusin
Catalog No: CFN99732
Aurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2.
Auraptene
Catalog No: CFN98787
Auraptene possesses anticarcinogenic, cardioprotective, anti-inflammatory, anti-oxidant, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene has a potential to attenuate chronic inflammation in adipose tissue and to improve obesity-related insulin resistance, and has protective effects in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells.
